Targeting the endothelium to prevent diabetes-related atherosclerosis.
Kearney
Mark T
MT
D050197:Atherosclerosis / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000378:metabolism
D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents; D009569:Nitric Oxide